Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice

Open Access

Peer-reviewed

Research Article

Stefan Nierkens,

Affiliation Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
⨯
Martijn H. den Brok,

Affiliation Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
⨯
Thijs Roelofsen,

Affiliation Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
⨯
Jori A. L. Wagenaars,

Affiliation Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
⨯
Carl G. Figdor,

Affiliation Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
⨯
Theo J. Ruers,

Affiliation The Netherlands Cancer Institute, Amsterdam, The Netherlands
⨯
Gosse J. Adema

* E-mail: g.adema@ncmls.ru.nl

Affiliation Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
⨯

Reader Comments (0)

Treatment guidelines
Is the Subject Area "Treatment guidelines" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Lymph nodes
Is the Subject Area "Lymph nodes" applicable to this article?

Thanks for your feedback.
Routes of administration
Is the Subject Area "Routes of administration" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.